NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME).

e-Meet @noxxon_pharma at #Sachs_ELSF

More info @ https://t.co/b7zJA2j8ns pic.twitter.com/MgkcKn6jOm

— Sachs Associates (@SachsAssociates) February 2, 2022